* Amgen Inc is expected to show a rise in quarterly revenue when it reports results on May 2 for the period ending March 31 2024
* The Thousand Oaks California-based company is expected to report a 21.8% increase in revenue to $7.436 billion from $6.11 billion a year ago, according to the mean estimate from 20 analysts, based on LSEG data.The company's guidance on February 6 2024, for the period ended March 31, was for revenue of $7.326 billion. (Sales/Revenue Majority Basis is on Total Revenue)
* LSEG's mean analyst estimate for Amgen Inc is for earnings of $3.87 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 12 "hold" and 3 "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by about 0.2% in the last three months.
* Wall Street's median 12-month price target for Amgen Inc is $320.00, above its last closing price of $276.38.
The company's guidance on February 6 2024 for the period ended March 31 was for Earnings before Interest and Taxes of USD3.15018 billion. Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 4.63 4.61 4.71 Beat 2.3
Sep. 30 2023 4.68 4.67 4.96 Beat 6.2
Jun. 30 2023 4.48 4.49 5.00 Beat 11.3
Jan. 1 0001 3.83 3.86 3.98 Beat 3.2
Jan. 4.09 4.10 4.09 Missed -0.1
1 0001
Sep. 30 2022 4.44 4.44 4.70 Beat 5.9
Jan. 1 0001 4.37 4.40 4.65 Beat 5.8
Mar. 31 2022 4.06 4.09 4.25 Beat 3.8
This summary was machine generated April 30 at 21:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments